MARKET

EGRX

EGRX

Eagle Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.20
+0.39
+0.69%
After Hours: 57.20 0 0.00% 16:10 11/15 EST
OPEN
56.81
PREV CLOSE
56.81
HIGH
58.14
LOW
56.14
VOLUME
165.91K
TURNOVER
--
52 WEEK HIGH
64.94
52 WEEK LOW
36.03
MARKET CAP
781.90M
P/E (TTM)
19.98
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EGRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EGRX News

  • Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors
  • Business Wire.1d ago
  • Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.3d ago
  • Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates
  • Zacks.3d ago
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.3d ago

More

Industry

Pharmaceuticals
+1.26%
Pharmaceuticals & Medical Research
+1.27%

Hot Stocks

Name
Price
%Change

About EGRX

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
More

Webull offers Eagle Pharmaceuticals Inc (EGRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.